Patients with colon cancer who consumed an anti-inflammatory diet during a phase III clinical trial showed longer overall survival post-treatment, compared to those on a proinflammatory diet, according to a Dana-Farber Cancer Institute analysis.
A series of preclinical studies show that a new compound, SHP1705, targets circadian clock proteins hijacked by glioblastoma stem cells, impairing the cancer cells’ ability to survive and grow.
University of Oklahoma researchers have discovered one reason why the brain tumor glioblastoma is so aggressive.
Researchers at the University of Texas Health Science Center at San Antonio have discovered a way to delay or even block recurrence of the deadliest brain cancer after radiation.
In a phase I study, rhenium obisbemeda (186RNL)—an investigational drug developed at the University of Texas Health Science Center at San Antonio—more than doubled median survival and progression-free time, compared with standard median survival and progression rates.
UCLA scientists have identified a potential new strategy for treating glioblastoma, the deadliest form of brain cancer, by reprogramming aggressive cancer cells into harmless ones.
David B. Weiner, of the Wistar Institute, and his laboratory, created a new therapeutic design for glioblastoma, the deadliest form of brain cancer.
Scientific progress often follows a prolonged path, but bioentrepreneur Samy Lamouille believes his dedication toward this pursuit will ultimately pay off for brain cancer patients.
The FY24 Defense Appropriations Act provides funding for the Glioblastoma Research Program to support research of high potential impact and exceptional scientific merit to reduce the burden of glioblastoma on service members and their families, veterans, and the American public. The managing agent for the anticipated program announcements/funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command.
The FY24 Defense Appropriations Act provides funding for the Glioblastoma Research Program to support high impact research to reduce the burden of glioblastoma on service members and their families, veterans, and the American public.
